• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [24105 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2012     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Treatment of obesity in patients with diabetes mellitus type 2 - Guideline synopsis and additional search for and assessment of systematic reviews]
2012     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) [Treatment of obesity in children and adolescents in primary and secondary care settings recommendations: clinical practice guidelines]
2010     Haute Autorite de sante (HAS) [Treatment of multiple missing teeth in adults with rare diseases by using implant-supported denture]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Treatment of mitral insufficiency with a percutaneous device with clip (TEER) in Quebec - characteristics, continuum of care and clinical outcomes of adult clientele treated between 2019-2020 and 2021-2022]
2007     The Netherlands Organisation for Health Research and Development (ZonMw) [Treatment of medication-resistant hallucinations with repetitive transcranial magnetic stimulation (rTMS)]
2016     The Swedish Council on Health Technology Assessment (SBU) [Treatment of maternal birth injuries following vaginal birth – mapping of systematic reviews]
2010     Committee for New Health Technology Assessment (CNHTA) [Treatment of lagophthalmos with gold weight implantation]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Treatment of haemophilia patients - Rapid report]
2000     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Treatment of gallstone patients]
2011     Institut national d'excellence en sante et en services sociaux (INESSS) [Treatment of esophageal cancer: systematic review on surgical techniques]
2010     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Treatment of early-stage breast cancer by conservative surgery and intracavitary balloon brachytherapy]
2009     The Regional Health Technology Assessment Centre (HTA-centrum) [Treatment of early rheumatoid arthritis with a combination of TNF-alpha inhibitors and methotrexate, versus methotrexate alone]
2005     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Treatment of depression]
2011     Norwegian Knowledge Centre for the Health Services (NOKC) [Treatment of chronic fatigue syndrome CFS/ME]
2011     Institut national d'excellence en sante et en services sociaux (INESSS) [Treatment of cancer-related secondary lymphedema]
2020     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Treatment of benign thyroid by thermal laser or radiofrequency ablation]
2011     Institute for Clinical Effectiveness and Health Policy (IECS) [Treatment of benign prostatic hypertrophy - Barreiro method]
2012     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Treatment of aortic stenosis with the sutureless ATS 3f Enable bioprothesis]
2006     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Treatment of alcohol abuse: a health technology assessment]
2008     The Regional Health Technology Assessment Centre (HTA-centrum) [Treatment of ADHD (Attention-Deficit/Hyperactivity Disorder) in adults with central stimulants]
2022     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Treatment of women with diastasis recti]
2011     The Regional Health Technology Assessment Centre (HTA-centrum) [Treatment in relapsed multiple myeloma; bortezomib, lenalidomide, thalidomide]
2021     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Treatment for postpartum psychiatric disorders - an evidence map]
2001     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Treatment for incontinence in Denmark]
2016     The Swedish Council on Health Technology Assessment (SBU) [Treatment for binge eating disorder]
2013     The Swedish Council on Health Technology Assessment (SBU) [Treatment duration for Lyme disease]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Treatment discussions: Does shared decision-making between doctor and patient regarding the choice of treatment lead to better results?]
2013     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Treatment by clinical psychologists; Literature overview on training, methods of treatment and areas of application]
2021     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Treatment and rehabilitation of people with fibromyalgia]
2013     Institut national d'excellence en sante et en services sociaux (INESSS) [Treatment and follow-up of children with sickle cell disease (SCD)]
2017     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Treatment and evaluation methods used in forensic psychiatry]
2006     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Treatment and care as assessed by patients and health care professionals - an analysis based on patients treated for colorectal cancer]
2013     Institut national d'excellence en sante et en services sociaux (INESSS) [Traumatic and non-traumatic spinal cord injury: a comparative analysis of the characteristics and organization of rehabilitation care and services in Québec]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Trastuzumab with pertuzumab in HER2-positive breast cancer]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Trastuzumab emtansine for breast cancer]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trastuzumab emtansine (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trastuzumab emtansine - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trastuzumab deruxtecan (NSCLC) – Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trastuzumab deruxtecan (gastric cancer) - Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trastuzumab deruxtecan (breast cancer) – Addendum to Commission A23-07]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trastuzumab deruxtecan (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trastuzumab deruxtecan (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trastuzumab deruxtecan (breast cancer, HER2+, at least 2 prior therapies) - Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trastuzumab deruxtecan (breast cancer, HER2+, at least 2 prior therapies) - Addendum to Commission A22-81]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trastuzumab deruxtecan (breast cancer, after 1 prior therapy) - Addendum to Commission A22-80]
2006     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Trastuzumab as adjuvant treatment of early breast cancer after surgical treatment]
2014     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Transvaginal mesh in pelvic organ prolapse repair]
2008     Committee for New Health Technology Assessment (CNHTA) [Transnasal endoscopy]
2010     The Netherlands Organisation for Health Research and Development (ZonMw) [Transmural nutritional support]
2011     The Netherlands Organisation for Health Research and Development (ZonMw) [Transmural care for hand eczema; a randomised controlled trial and cost-effectiveness evaluation]
2010     The Netherlands Organisation for Health Research and Development (ZonMw) [Transjugular intrahepatic porto-systemic shunt (TIPS) with Gore-tex covered stent-graft versus endoscopic treatment for acute bleeding of esophageal varices]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Transient elastography in non-alcoholic fatty liver disease]
2013     The Swedish Council on Health Technology Assessment (SBU) [Transient elastography in fibrosis staging]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Transient elastography (FibroScan®) for liver fibrosis staging]
2009     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Transient elastography (Fibroscan) for the diagnosis of liver fibrosis: a systematic review and meta-analysis]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Transcutaneous vagus nerve stimulation in pharmacoresistant epilepsy]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Transcutaneous vagus nerve stimulation in pharmacoresistant epilepsy –Third addendum to Commission E16-03]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Transcutaneous vagus nerve stimulation in pharmacoresistant epilepsy – Second addendum to Commission E16-03]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Transcutaneous vagus nerve stimulation in pharmacoresistant epilepsy - Addendum to Commission E16-03]
2023     Haute Autorite de sante (HAS) [Transcutaneous ultrasound-guided intravenous radiofrequency occlusion of the small saphenous vein]
2007     Andalusian Health Technology Assessment Area (AETSA) [Transcutaneous biosensors]
2011     Haute Autorite de sante (HAS) [Transcutaneous aortic valve implantation by the transfemoral or transapical route]
2008     Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT) [Transcranial magnetic stimulation]
2009     The Swedish Council on Health Technology Assessment (SBU) [Transcranial magnetic stimulation in treating depression]
2020     Canary Health Service [Transcranial magnetic stimulation for the treatment of cocaine addiction]
2022     Haute Autorite de sante (HAS) [Transcranial magnetic stimulation (rTMS) in the treatment of adult treatment-resistant depression]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Transcranial magnetic resonance-guided focused ultrasound for the treatment of essential tremor - Assessment according to §137h Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Transcranial magnetic resonance-guided focused ultrasound for the treatment of essential tremor - Assessment according to §137h Social Code Book V - Second addendum to commission H20-05]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Transcranial magnetic resonance-guided focused ultrasound for the treatment of essential tremor - Assessment according to §137h Social Code Book V - Addendum to commission H20-05]
2022     Norwegian Institute of Public Health (NIPH) [Transcranial direct current stimulation for depression and aphasia. A health technology assessment]
2023     Canary Health Service [Transcranial direct current stimulation device for the treatment of drug-resistant epilepsy]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Transcorneal electrical stimulation for retinitis pigmentosa]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Transcorneal electrical stimulation for retinitis pigmentosa (Addendum to commission E14-07)]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Transcervical radiofrequency ablation with intrauterine ultrasound guidance for uterine fibroids]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Transcervical radiofrequency ablation with intrauterine ultrasound guidance for uterine fibroids - Second addendum to commission H21-14]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Transcervical radiofrequency ablation with intrauterine ultrasound guidance for uterine fibroids - Addendum to commission H21-14]
2015     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Transcatheter mitral valve-in-valve implantation (TMViVI)]
2015     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Transcatheter implantable devices for mitral valve repair in adults with chronic mitral valve regurgitation (MitraClip®, Carillon®, NeoChord DS1000). German short version of the correspondent EUnetHTA assessment]
2012     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Transcatheter closure paravalvular leaks with Amplatzer]
2010     The Regional Health Technology Assessment Centre (HTA-centrum) [Transcatheter aortic valve prosthesis implantation (TAVI)]
2012     Institut national d'excellence en sante et en services sociaux (INESSS) [Transcatheter aortic valve implantation: Evaluation of the evidence and synthesis of organizational issues]
2017     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Transcatheter Aortic Valve Implantation Part I: A systematic review of health economic evaluations]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Transcatheter aortic valve implantation in severe aortic stenosis]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Transcatheter aortic valve implantation for severe aortic stenosis]
2015     Center for Drug Evaluation (CDE) [Transcatheter aortic valve implantation (TAVI) HTA report]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Transcatheter aortic prothesis implantation for the treatment of severe aortic stenosis]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Transbronchial lung cryobiopsy in diffuse interstitial lung disease diagnosis]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Transbronchial biopsy guided by endobronchial ultrasound (EBUS) in pathologies accesible by transbronchial puncture that required anatomopathological diagnosis]
2013     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Transapical and transfemoral aortic valve implantation: proposal of indicators for post-introduction observation]
2011     Committee for New Health Technology Assessment (CNHTA) [Transanal radiofrequency treatment of fecal incontinence]
2009     Committee for New Health Technology Assessment (CNHTA) [Transanal endoscopic microsurgery(TEM)]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Transanal endoscopic microsurgery (tem) and transanal minimally invasive surgery (tamis) for the treatment of rectal lesions]
2017     Agenzia sanitaria e sociale regionale, Regione Emilia-Romagna (ASSR) [Trancatheter ablation with cryoballoon for the treatment of atrial fibrillation. A rapid assessment]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trametinib: benefit assessment according to §35a Social Code Book V (dossier assessment)]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trametinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trametinib (melanoma) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trametinib (melanoma) - Addendum to Commission A18-60]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tralokinumab (moderate-to-severe atopic dermatitis in adolescents) - Benefit assessment according to § 35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tralokinumab (atopic dermatitis) - Benefit assessment according to §35a Social Code Book V]
2011     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Training therapy in physical medicine – Systematic Review]